Annual Meeting

2019 Annual Meeting

If you have a proposal that you would like us to include in our Proxy Statement and form of proxy for, or to present at the 2019 Annual Meeting of Stockholders, you must send the proposal to us by no later than December 14, 2018. Stockholders wishing to submit proposals or Director nominations that are not to be included in such Proxy Statement and form of proxy must do so no later than the close of business on January 23, 2019. Stockholders should also review our bylaws, which contain additional requirements with respect to advance notice of stockholder proposals and Director nominations.
 

2018 Annual Meeting

We are pleased to invite you to Ionis Pharmaceuticals, Inc.’s 2018 Annual Meeting of Stockholders. We will host the meeting at our offices in Carlsbad, California on Wednesday, May 23, 2018, at 2:00 p.m. Pacific Time. We will cover the formal items on the agenda during the Annual Meeting. Following the formal Annual Meeting, we will review the major developments of the past year and our plans for 2018, and answer your questions. 
 

2017 Annual Meeting

Ionis Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on May 24, 2017. The stockholders considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement dated April 6, 2017.

Proposal 1:

Election of directors to hold office until the 2020 Annual Meeting:

   

FOR

 

WITHHELD

 

BROKER 
NON-VOTES

Spencer R. Berthelsen

 

84,173,655

 

9,020,996

 

21,105,539

B. Lynne Parshall

 

87,494,494

 

5,700,157

 

21,105,539

Joseph H. Wender

 

84,148,943

 

9,045,708

 

21,105,539

The Company’s stockholders elected the foregoing candidates, by affirmative votes by a majority of the votes of the shares.

Proposal 2:

Approve an amendment to the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan:

FOR

 

AGAINST

 

ABSTAIN

 

BROKER NON-VOTES

81,668,509

 

11,359,170

 

166,972

 

21,105,539

The Company’s stockholders approved the foregoing proposal.

Proposal 3:

Approval, on an advisory basis, of the compensation paid to the Company’s executive officers, including the following resolution:

“RESOLVED, that Ionis’ stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2017 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.”

FOR

 

AGAINST

 

ABSTAIN

 

BROKER NON-VOTES

59,649,475

 

33,275,149

 

270,027

 

21,105,539

The Company’s stockholders approved the foregoing proposal.

Proposal 4:

Approval, on an advisory basis, of the frequency of holding an advisory vote on executive compensation:

FOR

 

AGAINST

 

ABSTAIN

 

BROKER NON-VOTES

92,187,838

 

272,627

 

624,013

 

110,173

Based on the results of this vote, and consistent with the recommendation of the Company’s Board of Directors, the Company will hold an advisory vote on executive compensation on an annual basis until the next required vote on the frequency of holding such an advisory vote, which is required at least once every six years.

Proposal 5:

Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for our 2017 fiscal year:

FOR

 

AGAINST

 

ABSTAIN

 

BROKER NON-VOTES

112,038,206

 

2,075,791

 

186,193

 

0

The Company’s stockholders approved the foregoing proposal.

 

 

©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.